Lisata Therapeutics, INC

Lisata Therapeutics announced a 72% workforce reduction, estimated $1.2 million in costs, and initiated legal action against Kuva Labs for breach of a merger agreement.

Lisata Therapeutics has terminated its merger agreement with Kuva Labs Inc. due to financing issues, triggering a $2 million termination fee and prompting a strategic review.

Lisata Therapeutics, Inc. and Kuva Labs Inc. have amended their merger agreement, extending the outside date to July 21, 2026.

Lisata Therapeutics and Kuva Labs Inc. have amended their merger agreement, extending key deadlines and outlining payment terms for delayed actions.

Lisata Therapeutics announced a delay in the commencement of its tender offer for common stock, citing ongoing negotiations with financing sources.

Lisata Therapeutics has amended its merger agreement with Kuva Labs, reducing the upfront cash payment to $4.00 per share while increasing the potential value of contingent value rights (CVRs) to $3.00.

Lisata Therapeutics reports Q1 2026 results, detailing progress on its proposed acquisition by Kuva Labs, Inc., and a net loss of $4.49 million.

Lisata Therapeutics reported a reduced net loss in the third quarter of 2025, driven by lower operating expenses, while its lead cancer drug certepetide showed promising clinical results in pancreatic cancer trials and secured new licensing deals.

Lisata Therapeutics reported a reduced net loss in Q2 2025, driven by lower operating expenses and initial revenue, while advancing its lead oncology drug, certepetide, and securing a new patent.

Lisata Therapeutics reports a net loss of $4.724 million for Q1 2025, with a focus on advancing its clinical-stage drug, certepetide, for solid tumor treatment.

Lisata Therapeutics reported a net loss of $4.9 million for the third quarter of 2024, with a focus on advancing its clinical-stage cancer therapies.

Lisata Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, while highlighting ongoing clinical trials for its lead drug candidate, certepetide.

Lisata Therapeutics, Inc. has filed an amendment to its 2025 Form 10-K to include previously omitted Part III information regarding corporate governance, executive compensation, and security ownership.

Lisata Therapeutics, a clinical-stage pharmaceutical company, details its financial performance for 2024 and provides an overview of its ongoing development programs.

Lisata Therapeutics' 10-K filing for the year ended December 31, 2023, highlights the company's financial status, clinical development programs, and regulatory landscape.

Lisata Therapeutics' President & CEO, David J. Mazzo, was granted 81,000 restricted stock awards and 40,000 stock options, while also selling 41,096 shares to cover tax liabilities.

Lisata Therapeutics' SVP James Nisco reported the grant of restricted stock and stock options, alongside tax-related share dispositions.

Lisata Therapeutics' SVP, Tariq Imam, acquired 15,000 restricted stock awards and 7,000 stock options, while also disposing of shares for tax liabilities.

Kristen K. Buck, EVP, R&D and CMO of Lisata Therapeutics, reported the acquisition of restricted stock and stock options, alongside shares withheld for tax liabilities.

Lisata Therapeutics Director Steven M. Klosk was granted 30,456 restricted stock units, increasing his beneficial ownership.

Lisata Therapeutics Director Heidi Henson was granted 30,456 restricted stock units, aligning her interests with shareholders.

Lisata Therapeutics has filed definitive additional materials related to its proxy statement with the SEC.

Lisata Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of directors, an amendment to the Employee Stock Purchase Plan, and the ratification of auditors.

Lisata Therapeutics has filed a definitive proxy statement with the SEC.

Lisata Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 27, 2024, to vote on director elections, equity incentive plan amendments, employee stock purchase plan amendments, auditor ratification, and executive compensation.